ACM
PBYI icon

AIGH Capital Management’s Puma Biotechnology PBYI Stock Holding History

AIGH Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-864,427
Closed -$6.06M – 62
2021
Q3 		$6.06M Sell
864,427
-250,000
-22% -$1.87M 1.27% 20
2021
Q2 		$10.2M Buy
1,114,427
+149,837
+16% +$1.52M 1.84% 16
2021
Q1 		$9.38M Buy
+964,590
New +$10.8M 1.97% 16

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AIGH Capital Management's PBYI Position: Q4 2021 in Review

AIGH Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 864,427 shares — an estimated $6.06M sold.

AIGH Capital Management first reported a position in PBYI in Q1 2021 and held it in 3 quarters. The position peaked at $10.2M in Q2 2021. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • AIGH Capital Management reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • AIGH Capital Management sold 864,427 Puma Biotechnology shares in Q4 2021, an estimated $6.06M.
  • AIGH Capital Management first reported a position in Puma Biotechnology in Q1 2021 and held it in 3 quarters.
  • AIGH Capital Management's Puma Biotechnology position peaked at $10.2M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on AIGH Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.